Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Ann Surg Oncol. 2021 Jul;28(7):3648-3655. doi: 10.1245/s10434-021-09696-3. Epub 2021 Mar 10.
Following radical orchiectomy, surveillance and primary retroperitoneal lymph node dissection (RPLND) are acceptable options for the management of early stage pure testicular teratoma in adult patients; however, there is no uniform consensus. The aim of this study was to investigate survival outcomes of adults with early stage pure testicular teratoma based on management strategy.
Data was extracted from the National Cancer Database (NCDB) from testicular cancer patients diagnosed with clinical stage (CS) I pure teratoma (pT1-4N0M0S0) between 2004 and 2014. Kaplan-Meier and Cox regression analyses were used to assess clinical outcomes based on management strategy.
Of the 61,167 patients diagnosed with testicular cancer, 692 (1.1%) had pure teratoma. Only individuals with CS I disease were considered (n = 237). The median age was 28 (23-35) years. Overall, 43 (18%) patients underwent RPLND and 194 (82%) patients were managed with surveillance. There was an increase in surveillance for CS I teratoma during the study period. Increasing distance from residence to treatment facility was an unadjusted predictor for undergoing primary RPLND (p < 0.001). Median follow-up was 54 months and there was no significant difference in overall survival between CS I teratoma patients managed with RPLND and those managed with surveillance (p = 0.13).
There has been a trend toward increasing adoption of surveillance for the management of early stage pure testicular teratoma in adults. Our findings suggest that surveillance provides comparable survival outcomes to primary retroperitoneal lymph node dissection in this setting.
在成人患者中,根治性睾丸切除术(RO)后,监测和原发性腹膜后淋巴结清扫术(RPLND)是早期纯精原细胞瘤的可接受的治疗方法,但尚未达成共识。本研究旨在根据管理策略探讨早期纯精原细胞瘤成人患者的生存结果。
从 2004 年至 2014 年期间,从国家癌症数据库(NCDB)中提取患有临床分期(CS)I 期纯精原细胞瘤(pT1-4N0M0S0)的睾丸癌患者的数据。采用 Kaplan-Meier 和 Cox 回归分析基于管理策略评估临床结果。
在诊断为睾丸癌的 61167 例患者中,有 692 例(1.1%)患有纯精原细胞瘤。仅考虑 CS I 期疾病患者(n=237)。中位年龄为 28 岁(23-35 岁)。总体而言,43 例(18%)患者接受了 RPLND,194 例(82%)患者接受了监测。在此期间,CS I 期精原细胞瘤的监测率有所增加。居住地与治疗机构之间的距离增加是接受原发性 RPLND 的未经调整的预测因素(p<0.001)。中位随访时间为 54 个月,接受 RPLND 治疗的 CS I 期精原细胞瘤患者与接受监测治疗的患者的总生存率无显着差异(p=0.13)。
在成人中,对早期纯精原细胞瘤的管理方法中,监测的应用趋势有所增加。我们的研究结果表明,在这种情况下,监测与原发性腹膜后淋巴结清扫术的生存结果相当。